文献速递乳腺外科围术期管理与 ERAS

日间乳腺手术后基于患者意愿的阿片类药物处方决策:一项随机临床试验

Patient-Based Decision-Making for Opioid Prescriptions after Ambulatory Breast Operation: A Randomized Clinical Trial.
PubMed 文献 · J Am Coll Surg · 2026-04-13

该随机临床试验纳入107例日间乳腺手术患者,比较基于患者主动选择(opt-in)的阿片类药物处方策略与常规处方。结果显示opt-in策略使处方率从100%降至35%,阿片类药物消耗和剩余量均显著减少,且未加重术后疼痛或影响生活质量。疼痛评分可独立预测阿片类药物使用。

要点

  • opt-in策略使日间乳腺手术后阿片类药物处方率从100%降至35%。
  • opt-in组阿片类药物消耗量和剩余量均显著低于常规处方组。
  • 两组术后峰值疼痛评分和生活质量评分无差异。

核心结论

  • 基于患者主动选择的阿片类药物处方策略可减少日间乳腺手术后的阿片类药物处方、消耗和剩余量,且不加重疼痛或降低生活质量。

研究设计与样本

  • 单中心随机临床试验,2022至2024年纳入107例成人日间乳腺手术患者,1:1随机分为POINT组(56例)和常规处方组(51例)。

主要发现

  • POINT组66%(37/56)患者选择不使用阿片类药物,34%(19/56)选择使用。
  • POINT组处方率为35%,对照组为100%,绝对降低65%。
  • POINT组9%患者实际消耗阿片类药物,对照组为24%,绝对降低15%。
  • POINT组共处方111片,对照组362片(中位数0[IQR 0-5] vs 6[IQR 5-7],p<0.0001);剩余量分别为95片和293片(中位数0[IQR 0-5] vs 6[IQR 5-7],p<0.0001)。
  • 总消耗量POINT组63片,对照组16片,但大多数患者未使用(两组中位数均为0[IQR 0],p=0.04);疼痛评分独立预测阿片类药物使用(OR 2.14,95%CI 1.41-3.26;p=0.00037)。

关键数值与推荐

  • 主要结局为术后第1至7天数字疼痛评分量表峰值疼痛评分(0-10分),非劣效界值为2分。
  • POINT组患者接受教育后仅在请求时开具阿片类药物。

临床怎么用

  • 在日间乳腺手术中可采用基于患者主动选择的阿片类药物处方策略,以减少不必要的处方和剩余药物。
  • 术后疼痛评分较高的患者更可能需要阿片类药物,可作为处方决策的参考。

局限性

  • 单中心研究,样本量较小(107例),结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Opioids are routinely prescribed after ambulatory breast surgery despite low reported pain, increasing risk of misuse and diversion. We conducted a randomized clinical trial to determine whether a patient opt-in prescribing strategy reduces opioid prescription, consumption, and excess without worsening postoperative pain or quality of life. STUDY DESIGN: Adults undergoing ambulatory breast surgery at a single tertiary center (2022 to 2024) were randomized 1:1 to Postoperative Opt-In Opioid Treatment (POINT) or routine opioid prescription. POINT patients received education and were prescribed opioids only on request. Primary outcome was peak pain scores 0 to 10 on the numeric pain rating scale on postoperative days 1 to 7 (noninferiority margin 2 points). Secondary outcomes included opioids prescribed, consumed, excess (prescribed minus consumed), PROMIS-29 quality-of-life change, and predictors of opioid use. RESULTS: Of 107 patients, 56 were randomized to POINT and 51 to control. In the POINT, 37 (66%) opted out and 19 (34%) opted in. Prescription rates were 35% in POINT vs 100% in controls (absolute reduction 65%). Nine percent were consumers vs 24% consumed opioids (absolute reduction 15%). A total of 111 pills were prescribed in POINT vs 362 in controls vs (median 0 [interquartile range (IQR) 0 to 5] vs median 6 [IQR 5 to 7], p < 0.0001), with excess of 95 vs 293 pills (median 0 [IQR to 5] vs 6 [IQR 5 to 7], p < 0.0001). Total pills consumed were 63 vs 16, although most patients used none (median 0 [IQR 0] in both groups, p = 0.04). Peak pain scores and quality-of-life scores did not differ. Pain scores independently predicted opioid use (odds ratio 2.14, 95% CI 1.41 to 3.26; p = 0.00037). CONCLUSIONS: A patient opt-in strategy reduced opioid prescribing, consumption, and excess without worsening pain or quality of life after ambulatory breast surgery.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Lofftus SY, Graham DS, Le J, et al. Patient-Based Decision-Making for Opioid Prescriptions after Ambulatory Breast Operation: A Randomized Clinical Trial. J Am Coll Surg. 2026. PMID: 41972433. doi:10.1097/XCS.0000000000001974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。